TDEVs contain tumor-specific molecular markers on their surfaces and within their structure, such as PSMA and STEAP1 in prostate cancer; EGFR and HER2 in bladder cancer; and CAIX in kidney cancer (Jansen et al., 2009). This evidence concerns the gene CA9 and prostate carcinoma.